TriSalus Life Sciences Projects 2026 Revenue Between $46M and $48M Following TriNav Advance Clearance
TriSalus Life Sciences (TLSI) reported significant growth in its third quarter, noting increases in revenue both year-over-year and quarter-over-quarter. This momentum is attributed to ongoing commercial expansion and improved utilization across customer accounts. Looking ahead, the company has provided a 2026 revenue outlook ranging from $46 million to $48 million. Management indicated that the recent clearance of TriNav Advance serves as a foundational catalyst intended to support key growth drivers heading into 2027.
